MétaCan
Menu
Back to cohort
Record W4404716645 · doi:10.1186/s13058-024-01922-6

Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies

2024· article· en· W4404716645 on OpenAlexaff
Jacob K. Kresovich, Catherine Guranich, Serena C. Houghton, Jing Qian, Micheal E. Jones, Maegan E. Boutot, Mitch Dowsett, A. Heather Eliassen, Montserrat García‐Closas, Peter Kraft, Aaron D. Norman, Michaël Pollak, Sabina Rinaldi, Bernard Rosner, Minouk J. Schoemaker, Christopher G. Scott, Anthony J Swerdlow, Roger L. Milne, Shelley S. Tworoger, Celine M. Vachon, Susan E. Hankinson

Bibliographic record

VenueBreast Cancer Research · 2024
Typearticle
Languageen
FieldMedicine
TopicGrowth Hormone and Insulin-like Growth Factors
Canadian institutionsMcGill University
FundersCancer Council VictoriaMedical Research CouncilNational Cancer InstituteNational Institutes of HealthDepartment of Health and Social CareNational Institute for Health and Care ResearchNational Health and Medical Research CouncilBreast Cancer Research FoundationRoyal Marsden NHS Foundation TrustWorld Health OrganizationWellcome Trust
KeywordsBreast cancerMedicineInternal medicineOncologyProspective cohort studyProlactinContext (archaeology)Surgical oncologyCancerRisk factors for breast cancerCohort studyRisk factorGynecologyHormoneBiology

Abstract

fetched live from OpenAlex

BACKGROUND: Prolactin, a hormone produced by the pituitary gland, regulates breast development and may contribute to breast cancer etiology. However, most epidemiologic studies of prolactin and breast cancer have been restricted to single, often small, study samples with limited exploration of effect modification. METHODS: The Biomarkers in Breast Cancer Risk Prediction consortium includes 8,279 postmenopausal women sampled from four prospective cohort studies, of whom 3,441 were diagnosed with invasive breast cancer after enrollment. Prolactin concentrations were measured for all study participants on plasma samples collected when all women were postmenopausal and before any breast cancer diagnosis using ELISA assays. Pooled, unconditional logistic regression models, adjusted for confounders, estimated odd ratios (OR) for associations of prolactin and postmenopausal breast cancer risk overall and stratified by breast cancer risk factors. RESULTS: Higher plasma prolactin concentrations were positively associated with postmenopausal breast cancer risk (> 13.2 ng/mL vs. < 7.9 ng/mL, OR: 1.20, 95% CI: 1.06, 1.36; P-trend < 0.001). Although associations did not appear to vary by time since blood draw or most breast cancer risk factors, associations were primarily observed in current users of postmenopausal hormones at blood draw (> 13.2 ng/mL vs. < 7.9 ng/mL, current users, OR: 1.58, 95% CI: 1.27, 1.96, P-trend < 0.001; non-current users, OR: 1.08, 95% CI: 0.93, 1.27, P-trend = 0.11; P-heterogeneity = 0.06). CONCLUSION: Prolactin may be a risk factor for postmenopausal breast cancer, particularly in the context of postmenopausal hormone use. Investigations of prolactin interactions with other hormonal factors may further inform breast cancer etiology.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.013
metaresearch head score (Gemma)0.014
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.013
Threshold uncertainty score0.068

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0130.014
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0040.014
Bibliometrics0.0040.004
Science and technology studies0.0000.000
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.043
GPT teacher head0.386
Teacher spread0.343 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueBreast Cancer ResearchSame topicGrowth Hormone and Insulin-like Growth FactorsFrench-language works237,207